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Abstract
Objectives. In patients with severe combined immunodeficiency
(SCID), the immune system often fails to eradicate maternal cells
that enter the foetus via the placenta, resulting in transplacental
maternal engraftment (TME) syndrome. However, the clinical
significance of TME has not been comprehensively elucidated.
Methods. Here, we describe a patient with SCID with a novel
frameshift IL2RG mutation associated with maternal engrafted
CD8+ T cells that had been expanded by viral infection. To evaluate
the origin of the expanded T cells, we HLA-typed the myeloid and
T cells of the patient and analysed the immunological
characteristics of the expanded CD8+ T cells using T-cell receptor
(TCR) repertoire and flow cytometry analysis. Results. In our
patient, the maternal engrafted CD8+ T cells expanded and exerted
in vitro antiviral function against human cytomegalovirus (CMV)
infection before and after haematopoietic cell transplantation
(HCT). After haploidentical HCT from the maternal donor, maternal
engrafted CMV-specific CD8+ T cells were maintained, successfully
proliferated and activated against CMV. We found no evidence of
acute graft-versus-host disease or infectious complications other
than recurrent episodes of CMV viraemia, which were well
controlled by ganciclovir and, possibly by, the maternal engrafted
CMV-specific CD8+ T cells. Conclusion. Our findings elucidate a
possible functional role of TME in controlling CMV infection in
patient with SCID and suggest an optimal strategy for donor
selection in patients with SCID with TME.
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OBJECTIVES
Severe combined immunodeficiency (SCID) is a
group of heterogeneous genetic diseases
characterised by fatal immune deficiency.1 The
most common cause of SCID in humans is variants
of the interleukin-2 receptor c (IL2RG) gene.2–5
Although some variations exist depending on the
degree of function of the variant alleles, SCID
often causes death during early infancy because
of life-threatening infections.
During pregnancy, maternal cells may transfer
to the foetus through the placenta, resulting in
microchimerism.6 In a healthy foetus, the immune
system eliminates these engrafted cells, but the
immune system in SCID may lack the functional
capacity to eliminate engrafted cells, resulting in
transplacental maternal engraftment (TME).7 In
patients with SCID, TME may result in graft-versus-
host disease (GVHD) even before haematopoietic
stem cell transplantation (HCT).8 However, the
clinical significance of TME in SCID remains poorly
understood.
Currently, the standard treatment for SCID is
allogeneic HCT in early life.9,10 As an alternative to
fully human leukocyte antigen (HLA)-matched
donors, parental haploidentical donors are usually a
more readily available source of stem cells. However,
deciding which parental donor is better and the
suitable degree of conditioning for HCT are unclear
for patients with SCID.11 Furthermore, because of
HCT-related morbidity and mortality, accurate
diagnosis of SCID is necessary before HCT is
performed. Here, we describe a patient with SCID
with a novel IL2RG mutation who had TME,
specifically engraftment of human cytomegalovirus
(CMV)-specific maternal CD8+ T cells. The engrafted
CD8+ T cells responded to CMV infection in the
patient with SCID by robustly expanding and exerting
antiviral function before and after maternal HCT.
RESULTS
Initial clinical course and diagnosis of SCID
with a IL2RG frameshift mutation
A 3-month-old Korean male infant was admitted
to the hospital with fever (Figure 1a). He was
born at full term from non-consanguineous
parents (Figure 1b), weighing 3250 g, with no
dysmorphic features. No family history of early
childhood death or recurrent infection was noted.
Immunisations were performed as scheduled,
including subcutaneous Bacillus Calmette–Guerin
(BCG) and oral rotavirus vaccines. Upon physical
examination, the infant’s general appearance was
normal and his vital signs were stable except for
the fever (≥ 39°C). We found no lymphadenopathy,
rash or hepatosplenomegaly. Laboratory tests
revealed leukopenia (white blood cell count
2170 µL1) and lymphopenia (absolute lymphocyte
count [ALC] 940 µL1), and thymic shadow was
absent on a chest radiograph. Despite empiric
antimicrobial treatment, the patient’s fever
persisted for more than a week. Further laboratory
tests revealed persistent lymphopenia and elevated
alanine aminotransferase (ALT, 346 IU L1), lactate
dehydrogenase (LDH, 2156 IU L1), ferritin
(> 16 500 ng mL1) levels, hypertriglyceridaemia
(279 mg dL1), elevated soluble CD25
(5790 U mL1) and low NK cell activity. Considering
the possibility of haemophagocytic
lymphohistiocytosis (HLH), a bone marrow biopsy
was performed, revealing haemophagocytosis.
However, some clinical and laboratory features,
such as a normal C-reactive protein level and no
clinical symptoms other than fever, were not
compatible with the diagnosis of HLH. Real-time
PCR was performed for Epstein–Barr virus (EBV) and
CMV to evaluate fever with unknown origin, and
early postnatal CMV infection was diagnosed
(Figure 1a, Table 1). We decided to treat the CMV
infection first. After starting intravenous
ganciclovir, the fever gradually disappeared and
the CMV levels decreased rapidly. Lymphocyte
subset analysis upon initiation of the CMV
treatment revealed low T-cell (22 µL1) and NK cell
(31 µL1) counts; however, B-cell counts (557 µL1)
were relatively maintained in the normal range.
Thus, we performed T-cell receptor excision circle
(TREC) screening and genetic testing for primary
immunodeficiency. The levels of TRECs were
extremely low, and targeted gene sequencing
revealed a novel variant of IL2RG (c.681del,
p.Phe227LeufsTer46) that resulted in a premature
termination codon in the extracellular domain of
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Figure 1. Diagnosis of SCID with a novel IL2RG mutation and engrafted transplacental maternal T cells. (a) First episode of CMV infection in this
patient. He was initially admitted to the hospital with a fever accompanied by leukopenia. (b) Pedigree showing affected individuals harbouring a
novel IL2RG mutation. Solid symbols indicate affected persons who were hemizygous for the mutant allele; half-solid symbols indicate
heterozygous individuals; void symbols indicate unaffected persons; circles represent female family members; and squares represent male family
members. *Genetic screening was not performed. (c) TREC results for SCID screening. < 40 copies lL1 was defined as negative.23 (d) Location
of the IL2RG mutation in our patient. The patient had a novel hemizygous frameshift mutation altering the extracellular domain (arrow) of the
interleukin-2 receptor c protein. (e) Flow cytometry analysis of CD132 expression by in vitro anti-CD3/CD-28-stimulated CD8+/CD4+ T cells and
ex vivo CD56+ NK cells from a healthy donor, heterozygous carrier (patient’s mother) and the patient. The mean fluorescence intensities (MFIs) of
isotype and CD132 are shown. (f) STAT5 phosphorylation after IL-2 stimulation (50 ng mL1). The ratio of the MFI of phospho-STAT5 (pSTAT5)
after IL-2 stimulation to isotype is shown. (g) HLA typing of myeloid cells and T cells from the patient and both parents.
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interleukin-2 receptor c (Figure 1c, d,
Supplementary table 1).
During the course of treatment with
intravenous ganciclovir, elevated liver enzymes
reappeared after the initial normalisation.
Moreover, the BCG injection site presented mild
suppuration, and splenomegaly with mesenteric
lymphadenopathy was observed on abdomen
ultrasonography. Treatment with anti-tubercular
drugs (isoniazid, rifampin and ethambutol) was
initiated with the impression of BCGitis, and the
serum liver enzymes were normalised.
Engraftment of maternal CD8+ T cells in the
patient with SCID
Intriguingly, the patient’s ALC and CD3+ T-cell
counts, particularly CD8+ T-cell counts, rapidly
normalised after hospitalisation day (HD) 8. On HD
23, the CD3+ and CD8+ T-cell counts were 1183 µL1
and 1150 µL1, respectively (Figure 1a, Table 1).
Next, we examined common c-chain (cC, CD132)
expression and IL-2-induced STAT5 phosphorylation.
T cells obtained from the patient on HD 43
expressed cC, similar to those from a healthy
control and the mother (carrier; Figure 1e). IL-2-
induced phospho-STAT5 was detected not only in T
cells from the healthy control and the carrier, but
also in the patient (Figure 1f). In contrast, cC and
IL-2-induced phospho-STAT5 were not detected in
NK cells from the patient. We hypothesised that
the expanded T cells originated from the mother
and transferred to the patient via the TME. HLA
typing of the patient and his parents showed that
T cells from the patient had identical haplotypes as
his mother, whereas myeloid cells had one
maternal haplotype and one paternal haplotype,
confirming that the expanded CD8+ T cells were
engrafted from the mother (Figure 1g).
Immunological characteristics of maternal
engrafted CD8+ T cells
We examined CD8+ T-cell cytokine production
following stimulation with various pathogenic
antigens. CD8+ T cells obtained from the carrier
produced IFN-c and/or TNF-a in response to CMV
pp65, CMV IE1, EBV BARF1 and purified protein
derivative (PPD), but did not respond to influenza A
virus (IAV; H1N1) MP1 or respiratory syncytial virus
(RSV) MSG. Interestingly, CD8+ T cells obtained from
the patient on HD 43 produced IFN-c and/or TNF-a
in response to only CMV pp65 and CMV IE1,
indicating that CMV-specific maternal CD8+ T cells
Table 1. Laboratory findings during first cytomegalovirus infection
Age
92D 97 ~ 99D 108D 114D 121 ~ 122D 132D 139D
Laboratory HD Normal HD 1 HD 6 ~ 8 HD 17 HD 23 HD 30 ~ 31 HD 41 HD 48
WBC 6000–14 000, µL1 2170 1680 5360 2940 2540 3250 3810
ALC 1500–3000, µL1 940 620 3230 1700 1010 2130 2670
Hb 10.5–14.0, g dL1 11.6 8.8 9.9 9.9 10.4 9.0 8.7
PLT 150–400, 9103 µL1 178 187 327 314 286 296 300
CRP 0–8, mg dL1 0.4 - < 0.3 < 0.3 < 0.3 < 0.3 < 0.3
TB 0.2–0.8, mg dL1 0.4 0.4 0.3 0.3 0.2 0.2 < 0.15
AST 13–34, IU L1 141 892 76 62 95 249 127
ALT 5–46, IU L1 192 346 85 60 96 155 122
LDH 119–247, IU L1 - 2156 345 259 276 - -
Ferritin 22–322, ng mL1 - > 16 500 1063.6 466.2 348 - -
CD3+ 2284–4776, µL1 - 22 - 1183 - - -
CD4+ 1523–3472, µL1 - 9 - 19 14 - -
CD8+ 524–1583, µL1 - 13 - 1150 744 - -
CD19+ 776–2238, µL1 - 557 - 502 246 - -
CD56+ 230–801, µL1 - 31 - 7 4 - -
IgG 176–601, mg dL1 - - - - - < 18 -
IgA 4.4–84, mg dL1 - - - - - < 5 -
IgM 17–105, mg dL1 - - - - - < 5 -
sCD25 158–623, U mL1 - 5790 - - - - -
CMV < 500, copies mL1 60 255 000 18 450 4880 11 900 < 500 < 500
WBC, white blood cell; ALC, absolute lymphocyte count; Hb, haemoglobin; PLT, platelet count; CRP, C-reactive protein; TB, total bilirubin; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; Ig, immunoglobulin; sCD25, soluble interleukin-2
receptor; CMV, cytomegalovirus; D, day; HD, hospitalisation day.
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Age (months) 4 5 6 7 8 9 10 11
( r l i )
at 9m after HCT
at 8m after HCT
at 11m after HCT
Discontinued    at 7m after HCT
Absolute lymphocyte count (cells µL−1) CD8+ T cell count (cells µL−1)
CD4+ T cell count (cells µL−1)CMV episode
Figure 2. Maternal engrafted CD8+ T cells exert antiviral functions against CMV before and after HCT in the patient with SCID. (a) Maternal
engrafted CD8+ T cells secreted TNF-a and/or IFN-c in response to CMV antigen (pp65, IE1), but not to other antigens. (b) TCR repertoire analysis
of CD8+ T cells from a healthy donor, mother (carrier) and the patient showed vigorous expansion of the oligoclonotypes of engrafted CD8+ T
cells from the patient. (c) Immunophenotyping demonstrating an increased frequency of effector/effector memory (CD45RACCR7) and
replicative senescent (CD28CD57+) CD8+ T cells from the patient. (d) Engrafted CD8+ T cells secreted higher levels of TNF-a and/or IFN-c in
response to CMV antigen after HCT than before HCT, and (e) exhibited a terminally differentiated immunophenotype, including effector/effector
memory and replicative senescent populations. (f) Schematic of the time course of disease and treatments. The patient underwent haploidentical
allogeneic HCT at the age of 6 months. Following HCT, there was no evidence of acute GVHD or disseminated infections, even with persistent
CMV viraemia.
ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology, Inc
2021 | Vol. 10 | e1272
Page 5
J-Y Koh et al. Antiviral maternal T cells in severe combined immunodeficiency
expanded in the patient in vivo during CMV
infection (Figure 2a). T-cell receptor (TCR) repertoire
analysis revealed that the top five clonotypes
represented ~ 45% of the total CD8+ T cells
obtained from the patient on HD 43, whereas the
top five clonotypes contributed to < 5% of the total
CD8+ T cells obtained from the healthy control and
the carrier, indicating vigorous expansion of
oligoclones in the patient (Figure 2b). Vigorous
expansion of oligoclones was also observed in the cd
T cells, although the proportion of cd T cells in the
patient decreased relative to that in the healthy
control and the carrier (Supplementary figure 1a–c).
These data indicate the oligoclonal expansion of
CMV-specific maternal CD8+ T cells in the patient.
These findings were supported by
immunophenotyping of na€ıve/memory cells. In the
carrier, the percentage of effector/effector memory
cells and CD57+CD28 replicative senescent cells
were 37.5% and 9.0%, respectively, among the total
CD8+ T cells. However, these values increased up to
97.8% and 66.7%, respectively, of the patient’s total
CD8+ T cells on HD 43 (Figure 2c).
Course before and after HCT
The patient underwent haploidentical allogeneic
HCT at 6 months of age. In the absence of a fully
matched donor, the maternal donor was selected,
and the patient was pretreated only with
antithymocyte globulin. Six weeks after HCT, we
examined cytokine production and
immunophenotypes of the patient’s CD8+ T cells.
CD8+ T cells continued to produce IFN-c and/or TNF-
a in response to CMV pp65 and CMV IE1, but not to
other antigens. In particular, the cytokine response
to CMV IE1 increased vigorously 41 days after HCT
(Figure 2d, Supplementary figure 2a). The
percentage of effector/effector memory cells among
total CD8+ T cells was maintained at a high level
(93.7%), and the percentage of CD57+CD28
replicative senescent cells increased to 84.3%
41 days after HCT (Figure 2e, upper). However, the
percentage of effector/effector memory cells among
CD8+ T cells was only 67.5% 197 days after HCT, and
the percentage of na€ıve cells increased to 15.9%.
Furthermore, the percentage of CD57+ CD28
replicative senescent cells decreased to 71.9%
(Figure 2e, lower). The total CD4+ T-cell count
(585 µL1 104 days after HCT) and percentage of
na€ıve cells among CD4+ T cells (51.9% 197 days after
HCT) also increased long-term after HCT
(Supplementary figure 2b, Supplementary table 2).
Collectively, these findings indicate successful
haematopoietic stem cell engraftment, resulting in
the reconstitution of both CD4+ and CD8+ T cells.
Following HCT, we found no evidence of acute
GVHD or other complications. CMV viraemia was
detected three times immediately before and
after HCT. However, the CMV titres (maximal titre,
3055–7750 copies mL1) were much lower than
those at the time of the initial infection
(> 5 9 106 copies mL1) and were successfully
reduced by ganciclovir treatment without
complications. Anti-mycobacterial treatment for
BCGitis was discontinued 9 months after HCT
(Figure 2f, Supplementary table 3).
These data indicate that engrafted CMV-specific
maternal CD8+ T cells harbouring antiviral activity
further proliferated and differentiated during the
course of HCT in the patient. The patient is
currently undergoing outpatient follow-up
13 months after HCT and is in good condition
without antimicrobial treatment or prophylaxis.
DISCUSSION
Here, we describe a patient with SCID with a
novel frameshift IL2RG mutation associated with
maternal engraftment of CD8+ T cells. TME
expansion in response to specific antigens,
including EBV, has been reported, but little is
known about the clinical significance and
immunological characteristics of TME.12–14 CMV
infection in patients with SCID during early
infancy can be a life-threatening complication.15
There have been many trials on controlling CMV
infection using donor-derived CMV-specific CD8+ T
cells, especially in recipients post-HCT.16–18 In our
patient, naturally engrafted CD8+ T cells expanded
and exerted presumed in vivo antiviral function
against CMV infection prior to HCT. These
findings indicate that engrafted CD8+ T cells
expanded in response to cognate antigens and
potentially engaged in a protective role against
CMV infection. Further studies, such as cytotoxic
assays against virus-infected cells, are required to
investigate the antiviral function of TME CD8+ T
cells against various viral infections.
In our patient, haploidentical HCT from the
maternal donor was performed. During the early
post-transplant course of HCT, CMV-specific
maternal engrafted CD8+ T cells successfully
maintained their antiviral effector functions,
indicating that they may contribute to the control
of CMV infection in the patient.
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In summary, this case reinforces the importance
of TREC screening and early diagnosis for SCID.2 In
addition, it provides knowledge about the possible
roles of maternal engrafted T cells in patients with
SCID for improved management and would be
informative for HCT in patients with SCID.
METHODS
This study was reviewed and approved by the Institutional
Review Board of Severance Hospital (Seoul, Republic of
Korea; 4-2020-0220). Informed consent was obtained from
the patient’s parents.
T-cell receptor excision circles (TRECs)
Blood collection was performed on a filter paper (903
ProteinSaver Snap-Apart Card; GE Healthcare,
Westborough, MA, USA) using the heel-stick technique. A
single punch was taken from a dried blood spot using a
1.5-mm puncher (Perkin Elmer, Waltham, MA, USA). The
assay was performed according to the instructions provided
in the EnLite Neonatal TREC Kit (Perkin Elmer).
Next-generation sequencing (NGS) panel
The xGen Inherited Diseases Panel (Integrated DNA
Technologies, Coralville, IA, USA) comprising 4503 genes,
including genes associated with various syndromic and non-
syndromic immunodeficiencies, was used. Genomic DNA was
extracted using the QIAamp DNA Blood Mini Kit (Qiagen,
Hilden, Germany). Approximately 500 ng of genomic DNA was
used, and the library was sequenced on a NextSeq 550 system
(Illumina, San Diego, CA, USA) with 2 9 151 bp reads. Reads
were aligned to human genomic reference sequences (GRCh37)
using the Burrows–Wheeler alignment (BWA) tool (0.7.12).19
HaplotypeCaller in the Genome Analysis Toolkit (GATK)
package (3.8-0) was used for variant calling, and ANNOVAR
and VEP (87) software were used for annotation.20–22
Surface antibody staining for flow
cytometry
Cryopreserved peripheral blood mononuclear cells (PBMCs)
were thawed and stained with fluorochrome-conjugated
antibodies against surface markers for 10 min at room
temperature. CD132 expression was evaluated after 6 h of
anti-CD3/CD28 stimulation (100 ng mL1 and 1 lg mL1,
respectively). Dead cells were excluded using LIVE/DEAD
red/aqua fluorescent reactive dye (Invitrogen, Waltham,
MA, USA). Multicolour flow cytometry was performed using
an LSR II instrument (BD Biosciences, Franklin Lakes, NJ,
USA), and the data were analysed using FlowJo software
(BD Biosciences; Supplementary table 4).
Cell sorting
T cells and myeloid cells were isolated from PBMCs for TCR
repertoire analysis and HLA typing of each subpopulation.
After staining with fluorochrome-conjugated antibodies, T
cells and myeloid cells were isolated using a FACSAria II
instrument (BD Biosciences).
TCR repertoire analysis
T-cell receptor repertoire diversity was analysed using the
LymphoTrack Dx TRG Assay Panel (Invivoscribe, Inc., San
Diego, CA, USA) and LymphoTrack Dx TRB Assay
Panel (Invivoscribe) on the NextSeq 550 system (Illumina).
HLA typing
HLA typing was performed using the AllType NGS Kit (One
Lambda, Inc., Los Angeles, CA, USA) on the NextSeq 550
system (Illumina). TypeStream Visual NGS Analysis Software
(One Lambda) was used for data analysis.
Antigen stimulation and intracellular
cytokine staining
Thawed PBMCs (approximately 1 9 106 cells) were
stimulated with soluble anti-CD3 (100 ng mL1; Miltenyi
Biotec) and overlapping peptides (EBV; BARF1, IFNA; H1N1,
RSV; MSG, and CMV; pp65, IE1 4 lg mL1 and JPT; PPD
10 lg mL1; Rockville, USA). After 13 h of stimulation,
brefeldin A (BD Biosciences) and monensin (BD Biosciences)
were added and culturing was continued for 11 h. The
cultured cells were then washed and stained with
fluorochrome-conjugated antibodies against surface
markers. After permeabilisation, intracellular cytokines were
stained and evaluated using flow cytometry.
Methanol fixation for analysis of
phosphorylated STAT5
Peripheral blood mononuclear cells (approximately 1 9 106
cells) were stained with antibodies against surface markers.
After washing, cells were treated with IL-2 (50 ng mL1) or
PBS for 10 min at 37°C, followed by incubation with IC
fixation buffer (Invitrogen) for 10 min at room temperature
and fixation with 100% cold methanol for 40 min at 4°C.
Cells were then stained with anti-human phosphor-STAT5
antibodies for 1 h at room temperature, followed by flow
cytometry.
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